Business
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
BANNOCKBURN, Ill., May 05, 2025--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":266,"url":"https://media.zenfs.com/en/business-wire.com/62d540b5815004432b66441a64e0933d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BOqyo0HRFLm3mtdGFS1UQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/62d540b5815004432b66441a64e0933d","width":480,"height":266}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":248,"url":"https://media.zenfs.com/en/business-wire.com/5d3c29217b31cdff3871f537ace68237"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AY9IuxRdJifuwzHKcO38mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ5NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5d3c29217b31cdff3871f537ace68237","width":480,"height":248}}},{"type":"text","content":"-New Technology Optimizes Plasma Collection Resulting in Efficiency Gains ","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"-Helps Strengthen Plasma Supply Used to Produce Lifesaving and Life-Sustaining Medicines","length":88,"tagName":"p","attribs":{}},{"type":"text","content":"BANNOCKBURN, Ill., May 05, 2025--(BUSINESS WIRE)--BioLife Plasma Services, part of Takeda (TSE:4502/NYSE:TAK), today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its U.S. network of plasma donation centers. The new Adaptive Nomogram is used on the Aurora Xi Plasmapheresis System, which is in more than half of BioLife's U.S. plasma donation centers. This new technology will be running in all BioLife donation centers using the Aurora Xi Plasmapheresis System by the end of December 2025.","length":536,"tagName":"p"},{"type":"text","content":"The new Adaptive Nomogram technology leverages a plasma donor’s unique body attributes, resulting in a more personalized plasma donation and a potential increase in the average amount of plasma collected. Three BioLife plasma donation centers participated in Fresenius Kabi’s clinical trial to provide data for the U.S. FDA’s premarket review of the new technology. The data collected by BioLife during the clinical trial successfully demonstrated a ~11.5% increase in plasma colle...